Sarepta Therapeutics, Inc. (SRPT) Balance Sheet

The D/E ratio improved from 1.44 in 2024Q1 to 0.68 in 2026Q2, driven by both debt reduction and equity accumulation, as retained losses narrowed from -$4.4B to -$4.6B over the period. This suggests the balance sheet is strengthening, but the path is uneven, with equity dipping to $1.1B in 2025Q1 and 2025Q4, reflecting quarterly losses and one-time charges. Investors should monitor whether this deleveraging trend persists given the lumpy revenue and margin volatility observed in the income statement.

Total debt has remained around $1.0B to $1.4B over the last ten quarters, with no significant repayment or new issuance, indicating the debt is likely long-term and not refinanced frequently. The D/E improvement is more attributable to equity growth from retained earnings improvements and possibly capital raises, rather than aggressive debt paydown. Given the company's volatile cash flows, with operating cash flow swinging from negative to positive, the fixed debt load could strain liquidity if revenue growth stalls, warranting close monitoring of interest coverage.

The reduction in total assets is driven by lower cash balances, which fell from $1.1B in 2024Q4 to $571.1M in 2026Q2, and a modest decline in net PPE, suggesting limited capital expansion. Goodwill remains minimal at around $30M, implying that acquisitions have not created significant intangible risk, which is positive for asset quality. The asset mix is relatively asset-light, with cash and receivables likely dominating, but the declining cash position could limit flexibility for R&D or commercial launches.

The accumulated deficit has not improved materially, moving from -$4.4B to -$4.6B over the period, which indicates that cumulative losses continue to outpace net income gains. The equity increase is likely attributable to capital raises or stock-based compensation, which adds to share count and dilutes existing shareholders. Investors should assess the quality of equity, as reliance on external capital rather than organic earnings may signal ongoing cash burn, consistent with the prior cash flow analysis showing cumulative operating cash flow negative.

The high current ratio suggests ample short-term assets to cover liabilities, but the absolute cash decline is concerning given the company's volatile operating cash flow, which swung from -$629.3M in 2025Q1 to $229.4M in 2025Q2. With total debt at $1.0B, the cash position covers only about 57% of debt, leaving limited buffer against operational shocks or unexpected R&D expenses. The liquidity position appears adequate for the near term, but the trend of declining cash warrants monitoring, especially if revenue growth does not stabilize.